Oxaliplatin with Fluoropyrimidine/Bevacizumab for Initial Therapy for Unresectable mCRC in Older Patients

“RCT in Japan showing NO BENEFIT of adding OX to FP + BEV as 1st line treatment in older adults with mCRC.

The authors did a crude vulnerability survey (VES-13) annd admit a more thorough GA would be helpful. Still, this helps inform conversation in the clinic.

Another successful study focused on older adults with cancer. In this case, ‘start low go slow’ is a reasonable strategy
–no compromise in efficacy
–better tolerability
–no difference in ability to receive 2nd line therapy

Would love to see differences in ability to maintain function (IADLS) and unplanned acute care received (ED, hospitalizations) which I suspect would be better in the less intensive treatment arm

Oxaliplatin Added Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)

Authors: Atsuo Takashima, Tetsuya Hamaguchi, Junki Mizusawa, Fumio Nagashima, Masahiko Ando, Hitoshi Ojima, Tadamichi Denda, Jun Watanabe, Katsunori Shinozaki, Hideo Baba, Masako Asayama, SeijiHasegawa, Toshiki Masuishi, Ken Nakata, Shunsuke Tsukamoto,  Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yukihide Kanemitsu, and Yasuhiro Shimada, on behalf of Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG)

Source: Ramy Sedhom/X

For more posts by Ramy Sedhom, visit oncodaily.com

Ramy Sedhom holds positions as Assistant Professor of Hematology and Oncology at Perelman School of Medicine and Director of Medical Oncology and Palliative Care at Penn Medicine’s Princeton Medical Center.

His work focuses on palliative care integration, geriatric assessment, psycho-oncology, caregiver distress, and remote patient monitoring, with publications in leading journals. Nationally, he contributes to guideline panels and committees, including the NCCN Guideline Panel for Older Adults with Cancer, and leadership roles within ASCO.